文献速递主动脉疾病

复杂性血管腔内修复术治疗近内脏感染性原生主动脉瘤

Complex Endovascular Repair of Paravisceral Infective Native Aortic Aneurysms.
PubMed 文献 · J Endovasc Ther · 2022-09-04

单中心前瞻性数据库研究纳入2013年12月至2020年6月连续26例近内脏感染性原生主动脉瘤患者,行复杂EVAR(24例SM-FEVAR,2例CHIMPS),围术期死亡11.5%,估计1年及3年生存率85%±7%,作者认为其中远期结果可接受,可作为开放手术的替代方案。

要点

  • 近内脏感染性原生主动脉瘤行复杂EVAR的30天/院内死亡率为11.5%(n=3)。
  • 估计1年和3年生存率均为85%±7%,3年免于晚期再干预率为100%。
  • 2例发生感染相关并发症,均在术后30天内出现新发感染性原生主动脉瘤,经EVAR治疗无死亡。

核心结论

  • 复杂EVAR治疗近内脏感染性原生主动脉瘤的早期和中期结果可接受,是开放手术可接受的替代方案。
  • 作者提出这类患者应接受长期抗菌药物治疗、移植物材料利福平浸渍和严格的术后监测。

研究设计与样本

  • 单中心前瞻性维护数据库识别2013年12月至2020年6月连续接受非择期复杂EVAR的近内脏感染性原生主动脉瘤患者。
  • 共纳入26例患者(19例男性;平均年龄67岁[SD=11.4];中位直径60 mm[IQR:55-73]),均有急性症状(n=24)或包裹性破裂(n=2)。
  • 所有患者均基于诊断标准被认为患有明确的感染性原生主动脉瘤;既往有主动脉修复史者被排除。
  • 手术方式为外科医生改良开窗EVAR(SM-FEVAR;n=24)或烟囱-潜望镜EVAR(CHIMPS;n=2)。
  • 中位观察随访时间为36.2个月(18.3-53.5)。

主要发现

  • 9例患者静脉血培养阳性,另有7例有近期或合并感染。
  • 所有患者均接受术前和术后抗生素治疗及利福平浸渍的覆膜支架。
  • 共计划保留95支血管,其中86支置入支架;1支血管术中闭塞,另3支在30天内闭塞。
  • 30天/院内死亡率为11.5%(n=3),估计1年和3年生存率(±SD)均为85%±7%。
  • 2例患者发生感染相关并发症,均在指数修复术后30天内出现新发感染性原生主动脉瘤,经EVAR治疗无死亡;估计3年免于晚期再干预率为100%。

临床怎么用

  • 作者提出这类患者应接受长期抗菌药物治疗、移植物材料利福平浸渍和严格的术后监测。
  • 临床影响部分指出,需要多学科协作以为这种具有挑战性的主动脉病变患者提供最佳可能结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the early and mid-term outcome of complex endovascular repair (EVAR) for paravisceral infective native aortic aneurysms (INAA). METHODS: Interrogation of a prospectively maintained database identified consecutive patients who underwent non-elective complex EVAR for paravisceral INAAs in a single institution between December 2013 and June 2020. All patients were considered to have definite INAAs based on diagnostic criteria. Patients who had prior aortic repair were excluded. RESULTS: A total of 26 patients (19 men; mean age 67 years [SD = 11.4]; median diameter 60 mm [IQR: 55-73]) with acute symptomatic (n = 24) or contained ruptured (n = 2) aneurysms underwent surgeon-modified fenestrated EVAR (SM-FEVAR; n = 24) or chimney-periscope EVAR (CHIMPS; n = 2). Median observed follow-up was 36.2 months (18.3-53.5). Nine patients had positive venous blood cultures and a further seven had recent or concomitant infection. All patients received pre- and post-operative antibiotic therapy and rifampicin-soaked endografts. A total of 95 vessels were targeted for preservation and 86 were stent-grafted. One vessel occluded intra-operatively and a further 3 occluded within 30 days. The 30-day/in-hospital mortality was 11.5% (n = 3), and the estimated 1- and 3-year survival (±SD) was 85% ± 7%. Infection-related complications (IRCs) occurred in two patients: both developed new INAA within 30 days of index repair and were treated by EVAR with no mortality. Estimated 3-year freedom from late re-intervention was 100%. One patient required infrarenal EVAR for a non-infective aneurysm at 43 months. CONCLUSION: Complex EVAR for paravisceral INAAs is associated with acceptable early and mid-term outcomes and is an acceptable alternative to open surgery. We propose that these patients are managed with long-term antimicrobials, impregnation of graft material with rifampicin, and rigorous post-operative surveillance. CLINICAL IMPACT: A multi-disciplinary approach is required to deliver the best possible outcome for patients with this challenging aortic pathology.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Juszczak M, Mann H, Riste M, et al. Complex Endovascular Repair of Paravisceral Infective Native Aortic Aneurysms. J Endovasc Ther. 2022. PMID: 36062747. doi:10.1177/15266028221119333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。